Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding childrens) meta-analysis

PROVENT, 2022
 
NCT04625725
RCTcilgavimab and tixagevimab (Evusheld)placeboCOVID-19 prophylaxis (excluding childrens)low
3460/1737 conclusif
  • demonstrated 77 % decrease in symptomatic Covid-19 (PE) with a high degree of certainty due to low risk of bias
  • suggested 96 % decrease in hospitalization with a high degree of certainty due to low risk of bias
reduced risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
BLAZE-2 US (Cohen), 2021
 
NCT04497987
RCTbamlanivimab monotherapyplaceboCOVID-19 prophylaxis (excluding childrens)some concern
588/587 conclusif
  • demonstrated 57 % decrease in infection (PCR positive symptomatic or not) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 1.0-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021
 
NCT04452318
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID-19 prophylaxis (excluding childrens)some concern
753/752 conclusif
  • demonstrated 83 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 2.0-fold increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).